ATE201827T1 - Methoden und mittel zur förderung der wundheilung - Google Patents
Methoden und mittel zur förderung der wundheilungInfo
- Publication number
- ATE201827T1 ATE201827T1 AT92907025T AT92907025T ATE201827T1 AT E201827 T1 ATE201827 T1 AT E201827T1 AT 92907025 T AT92907025 T AT 92907025T AT 92907025 T AT92907025 T AT 92907025T AT E201827 T1 ATE201827 T1 AT E201827T1
- Authority
- AT
- Austria
- Prior art keywords
- wound healing
- mip
- agents
- methods
- promoting wound
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title abstract 4
- 230000001737 promoting effect Effects 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003357 wound healing promoting agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
- G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/652,198 US5145676A (en) | 1981-09-08 | 1991-02-07 | Method and agents for promoting wound healing |
PCT/US1992/001026 WO1992013553A2 (en) | 1991-02-07 | 1992-02-07 | Method and agents for promoting wound healing |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE201827T1 true ATE201827T1 (de) | 2001-06-15 |
Family
ID=24615896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92907025T ATE201827T1 (de) | 1991-02-07 | 1992-02-07 | Methoden und mittel zur förderung der wundheilung |
Country Status (8)
Country | Link |
---|---|
US (1) | US5145676A (de) |
EP (1) | EP0579626B1 (de) |
JP (1) | JPH06505983A (de) |
AT (1) | ATE201827T1 (de) |
AU (1) | AU671073B2 (de) |
CA (1) | CA2103676A1 (de) |
DE (1) | DE69231860D1 (de) |
WO (1) | WO1992013553A2 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616688A (en) * | 1981-09-08 | 1997-04-01 | The Rockefeller University | Macrophage-derived inflammatory mediator (MIP-1α and MIP-1β) |
US5703206A (en) * | 1981-09-08 | 1997-12-30 | Univ Rockefeller | Macrophage inflammatory protein 2 (MIP-2) |
US5650147A (en) * | 1981-09-08 | 1997-07-22 | The Rockefeller University | Methods of stimulating granulocyte-macrophage progenitor cells |
US5741484A (en) * | 1981-09-08 | 1998-04-21 | The Rockefeller University | Macrophage-derived inflammatory mediator (MIP-1α and MIP-1β) |
EP0394409B1 (de) * | 1988-09-02 | 1997-06-11 | The Rockefeller University | Makrophagenabgeleiteter entzündungsmediator(mip-2) |
FR2648350B1 (fr) * | 1989-06-20 | 1994-07-01 | Roussel Uclaf | Utilisation de lipopolysaccharides extraits de bacteries gram(-) pour la fabrication d'un medicament facilitant la cicatrisation de la peau |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
JPH0782169A (ja) * | 1993-09-13 | 1995-03-28 | Toray Ind Inc | 創傷治療剤 |
US5602301A (en) * | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
US6451562B1 (en) | 1993-12-22 | 2002-09-17 | Human Genome Sciences, Inc. | Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides |
US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
US6488925B2 (en) | 1993-12-22 | 2002-12-03 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-4 (MIP-4) polypeptides |
US5504003A (en) * | 1994-03-08 | 1996-04-02 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-3 and -4 |
US6495129B1 (en) | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
US5522794A (en) * | 1994-06-16 | 1996-06-04 | Hercules Incorporated | Method of treating human wounds |
US5607388A (en) * | 1994-06-16 | 1997-03-04 | Hercules Incorporated | Multi-purpose wound dressing |
US5556375A (en) * | 1994-06-16 | 1996-09-17 | Hercules Incorporated | Wound dressing having a fenestrated base layer |
US5747600A (en) * | 1994-06-24 | 1998-05-05 | Fang; Ta-Yun | Reconstitutable polyacrylamide materials and methods for producing same |
US7091181B2 (en) * | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
US5935568A (en) * | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
US5733884A (en) | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5981231A (en) | 1996-06-17 | 1999-11-09 | Human Genome Sciences, Inc. | Polynucleotides encoding chemokine β-15 |
JPH10206424A (ja) * | 1997-01-21 | 1998-08-07 | Kitasato Inst:The | 創傷進展度測定検査方法、測定用キット、及び創傷面治療法決定方法 |
US5858991A (en) * | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
US6670337B1 (en) * | 1998-01-29 | 2003-12-30 | Yeda Reaearch And Development Co., Ltd. | Facilitation of wound healing with CM101/GBS toxin |
US6695824B2 (en) | 2001-04-16 | 2004-02-24 | The United States Of America As Represented By The Secretary Of The Army | Wound dressing system |
US7297343B2 (en) | 2001-07-31 | 2007-11-20 | Biosurface Engineering Technologies, Inc. | Bioactive medical films |
US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
US7435799B2 (en) * | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
WO2006135848A2 (en) * | 2005-06-10 | 2006-12-21 | Pamela Howard | Wound management system |
US9095562B2 (en) * | 2007-07-05 | 2015-08-04 | Regenerative Sciences, Inc. | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells |
WO2009085969A2 (en) * | 2007-12-19 | 2009-07-09 | Regenerative Sciences, Llc | Compositions and methods to promote implantation and engrafment of stem cells |
WO2009114785A2 (en) | 2008-03-14 | 2009-09-17 | Regenerative Sciences, Inc. | Compositions and methods for cartilage repair |
WO2010065854A1 (en) | 2008-12-05 | 2010-06-10 | Regenerative Sciences, Llc | Methods and compositions to facilitate repair of avascular tissue |
EP2643693A2 (de) * | 2010-11-23 | 2013-10-02 | KCI Licensing, Inc. | Vorrichtungen und verfahren zur diagnose und behandlung von wunden unter verwendung von biomarkern |
ES2803499T3 (es) | 2011-06-29 | 2021-01-27 | Biorestorative Therapies Inc | Composiciones y métodos de células grasas marrones |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
ATE149176T1 (de) * | 1987-10-02 | 1997-03-15 | Univ Rockefeller | Von makrophagen abstammender entzündungsvermittler(mip-1-alpha et mip-1-beta) |
EP0394409B1 (de) * | 1988-09-02 | 1997-06-11 | The Rockefeller University | Makrophagenabgeleiteter entzündungsmediator(mip-2) |
ATE129158T1 (de) * | 1989-07-10 | 1995-11-15 | Univ Rockefeller | Antikörper zu den aktivitätspromotoren eines kolonie stimulierenden faktors. |
PT98072B (pt) * | 1990-06-22 | 1998-11-30 | Chiron Corp | Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 alfa por metodos recombinantes e de composicoes farmaceuticas que os contem |
PT98073B (pt) * | 1990-06-22 | 1998-11-30 | Chiron Corp | Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 beta por metodos recombinantes e de composicoes farmaceuticas que os contem |
-
1991
- 1991-02-07 US US07/652,198 patent/US5145676A/en not_active Expired - Fee Related
-
1992
- 1992-02-07 AT AT92907025T patent/ATE201827T1/de not_active IP Right Cessation
- 1992-02-07 WO PCT/US1992/001026 patent/WO1992013553A2/en not_active Application Discontinuation
- 1992-02-07 CA CA002103676A patent/CA2103676A1/en not_active Abandoned
- 1992-02-07 DE DE69231860T patent/DE69231860D1/de not_active Expired - Lifetime
- 1992-02-07 EP EP92907025A patent/EP0579626B1/de not_active Revoked
- 1992-02-07 JP JP4506649A patent/JPH06505983A/ja active Pending
- 1992-02-07 AU AU14284/92A patent/AU671073B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JPH06505983A (ja) | 1994-07-07 |
WO1992013553A3 (en) | 1992-09-17 |
US5145676A (en) | 1992-09-08 |
EP0579626B1 (de) | 2001-06-06 |
EP0579626A1 (de) | 1994-01-26 |
CA2103676A1 (en) | 1992-08-08 |
AU1428492A (en) | 1992-09-07 |
WO1992013553A2 (en) | 1992-08-20 |
AU671073B2 (en) | 1996-08-15 |
DE69231860D1 (de) | 2001-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE201827T1 (de) | Methoden und mittel zur förderung der wundheilung | |
DE69027865D1 (de) | ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN | |
BR0211062A (pt) | Combinações para o tratamento de distúrbios inflamatórios | |
BR9707325A (pt) | Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma | |
UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
CY1105125T1 (el) | Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων | |
HUP9902429A2 (hu) | TNF-receptor-asszociált faktor (TRAF) modulátorok előállítása és alkalmazása | |
DK1059934T3 (da) | Matrixproteinpræparater til sårheling | |
DE3682229D1 (de) | Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate. | |
IT8720771A0 (it) | Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare. | |
TR200102107T2 (tr) | Tümör nekroz faktör antagonistleri ve endometriozda kullanımları. | |
DK1082131T3 (da) | Immunoregulator | |
NO984760L (no) | Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon | |
IT8821634A0 (it) | Composizioni farmaceutiche che favoriscono la cicatrizzazione di ferite e procedimento per prepararle | |
YU39598A (sh) | Upotreba duloksetina i njegova farmaceutska smeša | |
ES2089286T3 (es) | Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos. | |
MX9201258A (es) | Compuestos para el tratamiento del cancer y procedimiento para su preparacion. | |
BR9812489A (pt) | Uso de 6,7-substituìdas-2-aminotetralinas adequadas para a preparação de uma composição farmacêutica para o tratamento terapêutico de patologias inflamatórias e/ou autoimunes | |
ES2168772T3 (es) | Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina. | |
WO1996041607A3 (en) | Pharmaceutical compositions comprising restrictin p/activin a and use thereof as antagonist of il-6 and/or il-11 | |
DK0409040T3 (da) | Kolonistimulerende faktoraktivitetspromotorer | |
ATE315398T1 (de) | Synergistische, gold und ein corticosteroid enthaltende zusammensetzungen. | |
PT907737E (pt) | Muteina da il-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |